BNET Industries
Market Cap:$231.3M
Last Fiscal Year Sales:$28.7M
- Public
- US
Dow Jones Description
Spectrum Pharmaceuticals, Inc. (NASDAQ: SPPI), is a biopharmaceutical company that acquires, develops and commercializes a diversified portfolio of oncology and other drug candidates that meet critical health challenges for which there are few other treatment options. The Company's pipeline includes promising early and late-stage drug candidates with unique formulations and mechanisms of action that address the needs of seriously ill patients, such as at-home chemotherapy and new treatment regimens for refractory disease. Spectrum's passion to identify, develop and deliver better options for people suffering from cancer is behind every action they take. At Spectrum, everyone is committed to excellence and strives to make a difference every day.
Number of Employees 84
Contact Information
157 Technology Dr
Irvine, California 92618-2402
(949) 788-6700
Peer Companies
NAICS Code Pharmaceutical Preparation Manufacturing: 325412
Recent Events
-
Drug Maker Spectrum Signs Deal With Japanese Company
-
Spectrum touts increase in Zevalin sales
-
Spectrum Pharmaceuticals and Nippon Kayaku Collaborate to Develop Apaziquone in Asia
-
UPDATE 2-Spectrum says CMS OKs reimbursement of its cancer drug
-
Spectrum Pharmaceuticals Secures $50 Million from Institutional Investors
-
Unusual 11 Mid-Day Movers 9/8: OPXA, ITLN, CBY, ORH Higher; OSIR, UBSH, EXXI, SPPI Lower
-
Morgan Joseph Downgrades Spectrum Pharmaceuticals SPPI to Hold
-
PREVIEW-Spectrum's cancer drug expected to cross FDA hurdle
-
Spectrum Pharmaceuticals reports Q2 net loss
-
Spectrum Pharma Provides FDA With Addl. Details For Cancer Drug Zevalin - Update
-
Spectrum Pharmaceuticals, Inc. SPPI Receives $10 Million from Two Institutional Investors at $5.83 Per Share
-
Inside Wall Street
-
Spectrum Pharmaceuticals Receives $20 Million from Three Institutional Investors at $5.11 Per Share
News & Analysis
Filter by
spectrum pharmaceuticals inc. - All News and Analysis
Shorts Using Any Bad News They Can to Drive Spectrum Pharma Down
Seeking Alpha
- 2009-10-30
VFC submits: A comment from Arie regarding Spectrum Pharmaceuticals SPPI:I heard from seeking alpha guy justin that Spectrum may have cash around 156 million at the time. by VFC's Stock House
Spectrum Pharmaceuticals Is Worth a Close Watch
Seeking Alpha
- 2009-10-28
VFC submits: I received a lot of comments and feedback regarding Spectrum Pharmaceuticals SPPI earlier this month, and in my response I stated that I was looking for a buy price of under four dollars. The stock closed Tuesday at $4.12, not yet under four, but worth watching because...
Spectrum Pharmaceuticals: Undervalued and (Now) Oversold
Seeking Alpha
- 2009-09-24
ROUND ONE During the last pullback, Spectrum Pharmaceuticals SPPI began to sell-off on June 30 after shares of the company had reached the first new multi-year high since July 2007. On June 30, SPPI topped at $8.15 and closed at $7.65. by Justin M. Hall
Spectrum Pharma: Market Opportunities for Zevalin May Expand Significantly
Seeking Alpha
- 2009-09-13
Following the presentation by Spectrum Pharmaceuticals SPPI, which was held in front of a standing room only crowd of institutional investors, hedge fund managers and Wall Street banker types at the Rodman & Renshaw Healthcare Conference in New York, Dr. Andrew Sandler was mobbed with questions from members of the...
Spectrum Pharmaceuticals, Sequenom Shares Rise on Heavy Volume
Seeking Alpha
- 2009-09-01
Shares of Spectrum Pharmaceuticals (NASDAQ:SPPI) jumped on twice the average volume Monday. Shares for the biopharmaceutical company, which focuses on pioneering novel cancer therapies with a focus primarily in the areas of hematology-oncology and urology, are under a heavy accumulation which is related to Spectrum’s dealings with the FDA,...
Spectrum Pharma: Expect a Positive FDA Decision
Seeking Alpha
- 2009-08-23
Spectrum Pharma has a new article on BioMedReports.com. The article states that a decision on SPPI's SPPI drug Zevalin should have a decision made on September 7th. The article tagged Spectrum Pharma can be found here. This is good news for investors looking for the next breakout stock. The stock...
More Positive Developments for Spectrum Pharma
Seeking Alpha
- 2009-08-06
Spectrum Pharmaceuticals, Inc. SPPI, the biotechnology company with a primary focus in oncology, today announced that it has acquired 100% rights to RenaZorb®, a novel compound, being developed for chronic kidney disease - which is also a family of compounds represented by SPI-014, also known as RZB-014). The lanthanum-based...
Spectrum Pharmaceuticals: Oversold and Undervalued
Seeking Alpha
- 2009-07-14
In Monday trading, Spectrum Pharmaceuticals (Nasdaq: SPPI) closed at $4.98 with a market cap of $193 million. Shares broke through and closed below their 50-day MA, $5.02. This suggests that shares of the drug maker are likely oversold. Data Source: e-Signal. by Justin M. Hall
Spectrum: FDA News on Zevalin Equals an Approval
Seeking Alpha
- 2009-07-06
Spectrum Pharmaceuticals SPPI received a Complete Response letter from the FDA regarding its supplemental biologics License Application sBLA for Zevalin® (ibritumo-mab tiuxetan) for first-line consolidation setting for non-Hodgkin’s Lymphoma (NHL) patients. The FDA’s letter requested that Spectrum submits data files from the FIT study to support and verify...
Spectrum Pharmaceuticals: Temporary Setback
Seeking Alpha
- 2009-07-06
Yesterday, Spectrum Pharmaceuticals (Nasdaq: SPPI) announced receipt of a Complete Response Letter (CRL) for Zevalin from the FDA. SPPI submitted a supplemental Biologics License Application sBLA earlier this year for the use of Zevalin as a first-line consolidation therapy for the treatment of non-Hodgkin’s lymphoma (NHL). Zevalin is currently approved...
- 1
- 2
Industry Transcripts by Seeking Alpha
-
Palatin Technologies F1Q10 (Qtr End 9/30/09) Earnings Call Transcript
on Nov 16, 2009about PTN
-
Flamel Technologies SA Q3 2009 Earnings Call Transcript
on Nov 16, 2009about FLML
-
NexMed Inc. Q3 2009 Earnings Call Transcript
on Nov 10, 2009about NEXM
-
InterMune, Inc. Q3 2009 Earnings Call Transcript
on Nov 10, 2009about ITMN
-
Arena Pharmaceuticals Inc. Q3 2009 Earnings Call Transcript
on Nov 10, 2009about ARNA
Glass Door
Pharma Industry Companies
| Company | Employer Rating |
| Johnson & Johnson |  |
| Merck | |
| Pfizer | |
| Novartis |  |
| Abbott Labs | |
IndustryTop Rated
- How NOT to Write a Biotech Press Release: Just Ask Epeius 5 votes
- Biogen Idec's Social Media Ties Save Tysabri Again; FDA Watching 3 votes
- The 10 Weirdest Drug Stories of the Month 3 votes
- More Tysabri Problems; Time for a Biogen-Idec Credibility Check 3 votes
- Fired Whistleblower Reps Make Similar Claim: Pfizer Said They Lacked "Integrity" 3 votes
